Printer Friendly

miR-135a Alleviates Silica-Induced Pulmonary Fibrosis by Targeting NF-[kappa]B/Inflammatory Signaling Pathway.

1. Introduction

Exposure of silica (silicon dioxide) over several months can cause silicosis, a severe worldwide occupational or environmental lung disease with no effective therapies [1]. Epidemiological studies shows that the patients with silicosis are more likely to suffer tuberculosis and autoimmune disease [2, 3]. Inhalation of silica leads to the phagocytosis of free tiny particles by macrophages and the activation of epithelial cells in lung tissue which triggers the release of inflammatory mediators [4]. Inflammatory responses result in epithelial-mesenchymal transition (EMT) which stimulates fibroblast proliferation and the production of extracellular matrix (ECM) deposition, such as type I collagen (Col1) [5-8]. Excessive deposition of ECM causes progressive massive pulmonary fibrosis and impairment in respiratory functions [9]. The main histopathological characteristics underlying silicosis is quite investigated. However, the complicated biological and molecular mechanisms involved in lung damages have not yet been fully understood.

MicroRNAs (miRNAs), a class of endogenous short single-stranded noncoding RNAs of 22-25 nucleotides in length, are conserved in most eukaryotic cells. Primary miR-NAs (pri-miRNAs) are initially transcribed from the genome and cleaved to precursors of miRNA (pre-miRNAs) containing about 70 nucleotides. These pre-miRNAs can be exported to the cytoplasm where they are further cleaved to generate mature miRNAs. miRNAs can assemble into RNA-induced silencing complex (RISC) and guide the enzyme-containing complex to target the messenger RNA (mRNA) sequence, leading to the downregulation of gene expression through the cleavage of their target mRNAs and/or inhibiting their translation. miRNAs derived from 1-5% of human genome are responsible for silencing more than 30% of protein coding genes. Many noncoding miRNAs are involved in the physiological processes, and their abnormal expression affects several pathologies, including infectious diseases, cancer, and neurodegenerative diseases. Some evidence shows dysfunction of miRNAs in lung fibrosis [10, 11]. miR-135a exhibits downregulated expression in some diseases and cancers, and its upregulation can inhibit the inflammation, apoptosis, and cancer cell proliferation [12-14]. miR-135a also can suppress the cardiac fibrosis [15] but aggravates renal fibrosis in diabetic nephropathy [16]. miR-135a expression is increased in the lungs of antigen-exposed, sensitized mice [17]. miR-135a promotes inflammatory response in the lung tissues in monocrotaline- (MCT-) induced pulmonary arterial hypertension (PAH) in rats [18, 19] but inhibits migration and invasion in lung cancer cells [20]. However, the roles and molecular mechanisms of miR-135a in the silica-induced lung damages remain to be explored.

Phagocytosis of silica particles by macrophages is crucial for the inflammatory responses in the lung. The class B scavenger receptors (SR-B1) on the plasma membrane of macrophages recognize and tether silica particles then contribute to the subsequent canonical NLRP3 inflammasome activation [21] which requires not only nuclear factor kB-(NF-[kappa]B-) mediated upregulation of NLRP3 along with pro-IL-1b but also the assembly of multiple proteins including NLRP3, ASC, and pro-caspase-1 to activate caspase-1 [22, 23]. NF-[kappa]B and inflammasome activation are required for the silica-induced pulmonary inflammation and lung fibrosis [24-26]. NF-[kappa]B is a family of transcription factors and associates with inhibitors, I[kappa]B proteins under unstimulated conditions. I[kappa]B subunits confine NF-[kappa]B to cytoplasm and inhibit it to bind the promoter region of target genes. As a rapid-acting transcription factor, the free NF-[kappa]B subunit when separating from its inhibitors can translocate from the cytoplasm into the nucleus to promote gene transcription in response to stimuli or stress [27, 28]. The enhanced production of tumor necrosis factor-a (TNF-[alpha]), an inflammatory mediator which plays pivotal roles in the development of silica-induced lung damage [29], precedes the inflammasome activation in response to silica in lungs. Activation of TNF-[alpha] receptor is implicated in the ubiquitination and degradation of I[kappa]B [30, 31]. Activated NF-[kappa]B can bind to the promoter region of genes including TNF-[alpha] and collagens in lungs of mice exposed to silica [25, 32, 33]. Toll-like receptor 4 (TLR4) is a protein that in humans is encoded by the TLR4 gene. Activation of TLR4 results in activation of NF-[kappa]B. Because NF-[kappa]B plays important roles in the pathogenesis of silica-induced lung injury, it has been regarded as a potential target to weaken damage to lungs following silica exposure [26, 34, 35]. However, it is unclear whether miRNAs regulate the NF-[kappa]B pathway in silica-induced pulmonary fibrosis.

In the present study, miR-135a was identified to be downregulated in lung tissues where the expression of inflammatory mediators were significantly increased following silica exposure. Transduction of the lentivirus expressing miR-135a decreased the expression of inflammatory mediators in lung tissues of silica-treated mice and improved the silica-induced pulmonary fibrosis. miR-135a overexpression in lung tissues reduced p-p65 and TLR4 following silica exposure. Moreover, silencing endogenous miR-135a significantly increased the TLR4 protein level and enhanced the activation of the NF-[kappa]B pathway in BEAS-2B cells. In contrast, overexpression of miR-135a had opposite effects on TLR4 protein and activation of NF-[kappa]B in BEAS-2B cells. Injection of PDTC, an inhibitor of NF-[kappa]B, further enhanced the miR-135a-mediated improvement of inflammation and pulmonary fibrosis induced by silica. Taken together, our data indicate that miR-135a which is suppressed following silica inhalation alleviates the pulmonary fibrosis through targeting TLR4 to inhibit the NF-[kappa]B pathway.

2. Materials and Methods

2.1. Animals. Male C57BL/6 mice were housed in the Laboratory Animal Facility of Hunan SJA Laboratory Animal Co., Ltd. All animal experiments were performed in accordance with the guideline for the Care and Use of Laboratory Animals. For induction of pulmonary fibrosis by silica exposure, C57BL/6 male mice (6-week old) were anesthetized using sodium pentobarbital (Sigma-Aldrich, USA) through intra-peritoneal injection; then, the mice were intratracheally instilled with 50 [micro]l saline solution containing or no silica particles in suspension (50 mg/kg, Sigma-Aldrich, USA). The mice were sacrificed 4 weeks after silica instillation, and lung tissues were collected to be analyzed. For PDTC treatment, the mice were intraperitoneally injected with PDTC (100 mg/kg, Sigma-Aldrich, USA) or saline once daily from day 1 to day 21.

2.2. Hematoxylin and Eosin Staining and Assessment of Pulmonary Fibrosis. The lung tissues were fixed in 4% paraformaldehyde overnight at 4[degrees]C and then were embedded with paraffin wax. Five [micro]m thick sections were serially cut then stained using hematoxylin and eosin (H&E) to assess the severity of fibrosis. Briefly, the lung sections were deparaffinized with xylene then rehydrated in descending alcohol series. The sections were washed briefly in distilled water and stained in Harris' hematoxylin solution (Sigma-Aldrich, USA) for 10 minutes followed by washing in running water for 5 minutes. The sections were dipped in 1% acid alcohol for 30 seconds and washed in running water to remove excess dye from the sections then were dipped in ammonia water and rinsed in running water. The sections were counter-stained in eosin-phloxine solution for 30-60 seconds and dehydrated through graded alcohol in ascending order and cleared in xylene. The cell nuclei should be blue but the cytoplasm is pink to red in the sections.

The severity of pulmonary fibrosis was assessed according to the method described previously [36]; a score system ranging from 0 (normal lung) to 4 (total fibrous obliteration of the field) was employed in lung samples. The mean fibrosis score was measured from that of six random individual fields in each sections.

2.3. Real-Time Quantitative PCR. The lung tissues were removed to extract total RNA by TRIzol reagent (Thermo, USA). cDNA was synthesized with HiFi-Script cDNA synthesis kit (CoWin Biosciences, China) according to the instructions. Real-time PCR were conducted with the SYBR Green PCR Master Mix (Thermo, USA). The concentration of primer and probe for each target gene (miR-135a and inflammatory mediators) was optimized according to the instructions. [beta]-Actin gene served as a reference control. Relative gene expression were analyzed based on the [2.sup.-[DELTA][DELTA]t] method [37]. For each lung tissue, the target genes were examined in triplicate. All primer sequences for target genes are shown (Table 1).

2.4. Immunofluorescence. Staining on lung tissue sections was conducted as previously described [38]. 10 [micro]m cryosections were blocked with 5% normal goat serum in PBS containing 0.05% Triton X-100 for 1 hour (h) at room temperature (RT). Then sections were incubated with antibodies against E-cadherin (ab11512, Abcam), vimentin (#3932, CST), or [alpha]-SMA (14-9760-82, Invitrogen) at 4[degrees]C overnight. After washing with PBS, the sections were incubated with FITC-conjugated secondary antibody for 1 h at room temperature. Normal serum was used as negative control. Fluorescence signals were examined using the Nikon Eclipse E600 fluorescence microscope (Nikon, Tokyo, Japan). Representative images were captured from at least 15 random regions in a blinded manner for each experiment, and the mean intensity was analyzed using the ImageJ software (available at https://rsb.info.nih.gov/ij/, Bethesda, MD, USA). The nuclei were stained with DAPI in PBS (Molecular Probes) for 10 min.

2.5. Western Blot. Changes in the expression levels of proteins in the mice lung tissues were examined by western blotting. Briefly, the lung tissue were homogenised in a lysis buffer (RIPA lysis buffer: 25 mM Tris-HCl pH7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA pH 8.0 with 1 mM PMSF, 1mM [Na.sub.3]V[O.sub.4], and Protease Inhibitor (Cocktail-P2714, Sigma)). Protein lysate (30 ng) was subjected to SDS-PAGE gel. Then proteins were transferred from the gels to PVDF membrane. The membranes were blocked with 5% nonfat milk in TBST (20 mM Tris-HCl, 150 mM NaCl, and 0.05% tween-20) and incubated with anti-p65 antibody (ab16502, Abcam), anti-p-p65 antibody (ab86299, Abcam), anti-TLR4 antibody (19811-1-AP, ProteinTech), anti-p-I[KAPPA]B[alpha] (ab133462, Abcam), anti-I[KAPPA]B[alpha] (ab32518, Abcam), anti-pIKK[alpha] (ab38515, Abcam), anti-IKK[alpha] (ab32041, Abcam), or anti-[beta]-actin antibody (60008-1-Ig, ProteinTech) at 4[degrees]C overnight. Then, the corresponding secondary antibodies (1 : 5000, ProteinTech) conjugated with HRP were applied for 90 min at room temperature. The membranes were exposed to ECL (#6883, CST Signal Fire[TM] ECL). The bands were analyzed by the ImageJ software. The levels of target proteins were normalized by [beta]-actin.

2.6. Lentivirus Vector System. pri-miR-135a or negative control sequences were inserted into the pGCsil-GFP vector (GENECHEM) to generate a lentivirus-mediated miR-135a construct (LV-miR-135a) and lentivirus control vector (LV-control). The virus packaging process was as follows. In details, the LV-miR-135a or LV-control construct (20 [micro]g) with the pHelper 1.0 packaging vector (15 [micro]g) and pHelper 2.0 envelop vector (10 [micro]g) was cotransfected into the HEK293T cells using Lipofectamine 2000 (Invitrogen). The culture medium was collected and concentrated by ultracentrifugation after 48 h of transfection. The virus were aliquoted and stored at -80[degrees]C. The final titer of lentivirus was 5 * [10.sup.11] vg/ml.

2.7. Transduction of Lentivirus in Lung Tissues. The mice (6-week old) were anesthetized by sodium pentobarbital and intratracheally instilled with 60 [micro]l LV-control or LV-miR-135a (5 * [10.sup.11] vg/ml). Fourteen days later, the mice were treated with silica or saline. Lung tissues were removed to be analyzed after 3 weeks following treatment.

2.8. BEAS-2B Cell Culture and Transfection. BEAS-2B cells were cultured in 10% FBS 1640 medium. Hsa-miR-135a mimic (50 nM) or inhibitor (100 nM) was transfected into cells with Lipofectamine 2000 (Invitrogen) according to the manufacturers' instructions for DNA plasmids.

2.9. Statistics. All data were expressed as the mean [+ or -] SEM. Analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). Differences between groups were calculated using the one-way ANOVA test. Correlation of the miR-135a expression with fibrosis severity was examined using the Pearson correlation. A p value < 0.05 was considered as statistical significance.

3. Results

3.1. Silica Induces Pulmonary Fibrosis in Mice. miR-135a has antifibrosis effects in the heart [15]. In order to investigate the role(s) of miR-135a in the silica-induced pulmonary fibrosis, the mice was instilled intratracheally with silica to induce pulmonary fibrosis. HE stain for lung sections exhibited much more sever fibrosis 28 days following silica instillation, when compared with control (Figure 1(a)). We employed the grading numerical scale 0-4 to determine the severity of lung fibrosis [36]. Scale 0 indicates the absence of fibrosis but scale 1 to 4 represents light to intense fibrosis. The score of fibrosis was much higher in the lung sections from mice exposed to silica than that from control mice which exhibited scale 0 for fibrosis (Figure 1(b)).

Silica caused the decrease in epithelial cells but increase in mesenchymal cells in the lungs. We found the global lower expression of E-cadherin, an epithelial cell marker (Figure 1(c)). These data indicate silica instillation results in pulmonary fibrosis.

3.2. Decreased Expression of miR-135a in Lung Tissues from Silica-Instilled Mice. RNAs were extracted to detect the expression of miR-135a and inflammatory mediators including IL-1b, TNF-[alpha], TGF-[beta], and IFN-y in lung tissues from control and silica-instilled mice using real-time quantitative fluorescence PCR (QF-PCR). It was observed that the levels of IL-1, TNF-[alpha], TGF-[beta], and IFN-y were significantly upregulated in silica-instilled lungs (Figures 2(a)-2(d)), indicating silica-induced inflammatory responses in lung fibrosis. However, expression of miR-135a was much lower in lung tissue following silica exposure, when compared to controls (Figure 2(e)). Moreover, miR-135a expression showed high negative correlation with score levels for fibrosis in lung tissues following silica instillation (Figure 2(f)). These data indicate miR-135a probably has inhibition effects on the silica-induced lung fibrosis.

3.3. miR-135a Restoration in Lung Tissues Attenuates Pulmonary Fibrosis. Since silica instillation significantly decreased miR-135a expression in lungs and it probably suppressed the silica-induced pulmonary fibrosis, we next overexpressed miR-135a in the lungs through intratracheal instillation of lentivirus carrying either miR-135a or control gene to determine the roles of miR-135a in pulmonary fibrosis. The mice were exposed to silica 14 days after lentivirus instillation. Lung tissues were analyzed 21 days following silica exposure. miR-135a level in lungs was dramatically increased after instillation of LV-miR-135a, compared to LV-Ctrl instillation and miR-135a expression was downregulated following silica exposure (Figure 3(a)). HE stain revealed severe silica-induced fibrosis in lung sections from mice overexpressed control gene. But silica-induced fibrosis was alleviated in the lungs of mice overexpressed miR-135a (Figure 3(b)), which were consistent with the quantitative data showing a lower score of fibrosis in miR-135a-overexpressed mice, when compared to controls mice following silica exposure (Figure 3(c)).

Fibrosis was further evaluated by the expression of markers for epithelial cells or mesenchymal cells in lung sections. Restoration of miR-135a elevated E-cadherin expression and lessened [alpha]-SMA expression following silica instillation (Figures 3(d) and 3(e)). However, vimentin showed no obvious change after silica exposure (Figure 3(f)). These collective data indicate miR-135a restoration alleviates silica-induced pulmonary fibrosis.

3.4. miR-135a Restoration in Lung Tissues Attenuates Inflammatory Response in Silica-Induced Pulmonary Fibrosis. Expression of inflammatory mediators was further monitored by QF-PCR. Consistently, expressions of IL-1b, TNF-[alpha], TGF-[beta], and IFN-y were dramatically increased following silica, but their expression showed much weaker in miR-135a-overexpressed lungs, compared to the control mice following silica exposure (Figure 4), indicating miR135a restoration attenuates inflammatory response in silica-induced pulmonary fibrosis.

3.5. miR-135a Restoration in Lung Tissues Inhibits NF-[kappa]B Signal in Silica-Induced Pulmonary Fibrosis. The NF-[kappa]B signaling pathway aggravates inflammatory reactions in silica-induced fibrosis; WB results showed an increase in p-p65, one component of NF-[kappa]B complex, in lungs after silica exposure. miR-135a overexpression reduced the p-p65 level following silica instillation, compared to control mice (Figures 5(a)-5(c)). Activation of TLR4 (Toll-like receptor 4) results in an increase of p-p65, and silica exposure led to an increase in TLR4, but miR-135a overexpression decreased TLR4 level (Figures 5(a) and 5(d)). Although there were no predicted target sites of miR-135a in 3'UTR of TLR4 or NF-[kappa]B components using the TargetScan Release 6.0, we applied gain- and loss-of-function experimental strategies to investigate whether miR-135a regulates the expression of TLR4 and NF-[kappa]B components. Transfection of miR-135a inhibitor into BEAS-2B cells to silence endogenous miR135a upregulated the TLR4 protein level and enhanced the activation of the NF-[kappa]B pathway. In contrast, transfection of hsa-miR-135a into BEAS-2B cells had opposite effects on TLR4 protein and NF-[kappa]B activation (Figures 5(e)-5(l)). These data together indicate miR-135a restrains NF-[kappa]B activation probably through targeting TLR4 in silica-induced pulmonary fibrosis.

3.6. Inhibition of NF-[kappa]B Improves miR-135a-Mediated Protective Effects on Silica-Induced Pulmonary Fibrosis. Since NF-[kappa]B activation facilitates the silica-induced inflammation and fibrosis, we further investigated whether miR-135a weakened inflammation and fibrosis through the regulation of NF-[kappa]B activation. Silica-induced fibrosis were detected in miR-135a-overexpressed mice after intraperitoneal injection of PDTC, an inhibitor of NF-[kappa]B signaling. The level of p-p65 and TLR4 showed much lower in mice when miR-135a overexpression was combined with PDTC treatment, compared to saline group (Figures 6(a)-6(d)). Consistently, miR-135a overexpression inhibited silica-induced fibrosis. PDTC treatment further hindered the fibrosis development in miR-135a-overexpressed mice (Figures 6(e) and 6(f)). And inhibition of PDTC on the fibrosis was consistent with the further elevated expression of E-cadherin but further depressed the level of [alpha]-SMA in miR-135a-overexpressed mice with PDTC injection (Figures 6(g) and 6(h)). PDTC injection had no effect on vimentin expression (Figure 6(i)). Therefore, inhibition of NF-[kappa]B improves miR-135a-mediated protective effects on silica-induced pulmonary fibrosis.

3.7. Inhibition of NF-[kappa]B Improves the Anti-Inflammatory Effect of miR-135a in Silica-Induced Pulmonary Fibrosis. Silica-induced inflammation was also detected in miR-135a-overexpressed mice after intraperitoneal injection of PDTC. PDTC treatment elevated the miR-135a expression (Figure 7(a)). The expression of inflammatory mediators, IL-1b, TNF-[alpha], TGF-[beta], and IFN-y were weakened in miR-135a-overexpressed mice following silica exposure. Their expression levels were further reduced after PDTC injection in miR-135a-overexpressed mice (Figures 7(b)-7(e)), indicating inhibition of NF-[kappa]B enhances miR-135a-mediated amelioration of inflammation and pulmonary fibrosis induced by silica. Taken together, these collective data indicate that miR-135a probably improves pulmonary fibrosis and inflammatory responses through the regulation of the NF-[kappa]B pathway. Silica-induced decrease in the expression of miR-135a disrupts its protective effects on the inflammation and pulmonary fibrosis.

4. Discussion

In this study, we identified miR-135a as a protective factor to alleviate silica-induced inflammation responses and pulmonary fibrosis through inhibition of NF-[kappa]B activation. Silica exposure resulted in the reduction of miR-135a expression to restrain the protective pathway.

Silica exposure leads to inflammatory reactions which aggravates the abnormal synthesis and deposition of collagen in the lung. There is lack of effective treatment on the lung fibrosis after silica exposure, which prompts scientists to focus on exploring the molecular mechanisms of fibrosis development. miRNAs mediate mRNA translational repression or destabilization and regulate gene expression. miRNAs show a spatial specific expression. In recent years, miRNAs are considered as new targets for fibrosis in various tissues. Let-7i suppresses the expression of interleukin-6 (IL-6) and collagens to inhibit angiotensin II-induced cardiac fibrosis [39]. miR-125b and miR-22 are significantly downregulated in liver tissues from patients with liver fibrosis [40]. miRNAs are also reported to be involved in the pathogenesis of various pulmonary diseases [41]. miR-29 prevents the phosphorylation of PI3K-AKT induced by TGF-[beta]1 and reduces extracellular matrix synthesis in human lung fibroblasts [42]. Let-7d is downregulated in lungs from patients with idiopathic pulmonary fibrosis (IPF). Inhibition of Let-7d triggers epithelial to mesenchymal transition (EMT) [43].

miR-135a has shown the protective effects under some conditions. Our study showed miR-135a expression was decreased and restoration of miR-135a improved the pulmonary fibrosis. miR-135a also suppresses the infiltration of eosinophils and mast cells into the nasal mucosa and alleviates allergen-induced inflammation [44]. Moreover, miR135a overexpression protects human umbilical vein endothelial cell (HUVEC) injury induced by mechanical stretch [45]. miR-135a targets NHE9 to limit the growth and migration of glioblastoma cells [46]. However, miR-135a facilitates the development of some diseases as well. miR-135a accelerates renal fibrosis through the regulation of TRPC1, which increases the synthesis of extracellular matrix proteins in diabetic kidney injury [16]. miR-135a ablation represses pancreatic cancer growth in vivo [12]. miR-135a acts as an onco-miRNA to promote proliferation of a bladder cancer cell by targeting PHLPP2 and FOXO1 [47]. Therefore, the effects of miR-135a on diseases depend on its target genes.

Evidence supports miRNA-based strategies as a novel therapeutics treatment and prevention for some diseases. Administration of miravirsen which targets miR-122 decreases viral RNA levels in patients with chronic hepatitis C in clinical phase 2a trial, indicating amelioration of liver fibrosis [48]. A study applies lipid vehicle to deliver miR34a to inhibit lung tumors burden in mice [49]. It is also reported that restoration of miRNA expression probably represents a novel treatment for the pathology of IPF [50]. The present study showed the delivery of miR-135a improved the silica-induced fibrosis and inflammation, indicating treatment strategy targeting miR-135a provides potential benefit for the patients. However, systemic introduction of miRNAs have side effects. Delivery of the miRNA therapeutic to the target tissue remains a big challenge.

Inflammatory response is a complex physiological reaction to noxious stimuli including silica. But its dysregulation often causes a variety of pathologies such as fibrosis. Several miRNAs, including miR-133a, miR-29, miR-221, miR-223, miR-155, and miR-652, are known to play roles in specific inflammatory diseases [40]. miR-326 regulates expression of TGF-[beta]1 and other profibrotic genes such as Smad3, Ets1, and matrix metalloproteinase 9 (MMP9) in IPF [51]. Silica-induced collagen deposition causes silicosis that is directly controlled by cytokines. Silica activates NF-[kappa]B that enhances the expression of TNF-[alpha], one of the most important cytokines. Some miRNAs are reported to regulate NF-[kappa]B. miR-892b activates NF-[kappa]B activity in breast cancer cells [52]. miR-181b inhibits the activation of the NF-[kappa]B signaling pathway to regulate vascular inflammation [53]. And miR-26a inhibits NF-[kappa]B activity to attenuate collagen I expression in cardiac fibroblast [54]. The present study showed miR-135a restoration attenuated the level of p-p65, one component of NF-[kappa]B complex in silica. But it remains unexplored how miR-135a restrains the level of p-p65 and whether miR-135a binds to mRNA of p65 or other molecules that phosphorylate p65. Although TLR4 expression was regulated by miR-135a in BEAS-2B cells, there were no predicted target sites in TLR4 or NF-[kappa]B components. Therefore, it remains unexplored how miR-135a confines TLR4 level and NF-[kappa]B activation. It is also unknown whether miR-135a regulates other pathways or molecules to alleviate the silica-induced pulmonary fibrosis.

Our data showed miR-135a was downregulated following silica exposure. But it is unclear how miR-135a expression is controlled in silica-induced pulmonary fibrosis. One of the oncogene, C-myc, associates the promoter region of miR-122 to control its expression [55]. Inflammatory mediators also affect miRNAs expression. IL-6 and Stat3 bind to upstream promoter region of miR-21 and increases its expression in human hepatocytes and hepatic stellate cells (HSC) [56]. TGF-[beta] can suppress miR-29 or Let-7d expression [57]. miR-181b expression is regulated by TNF-[alpha] in endothelial cells (ECs) [53]. Evidence also shows NF-[kappa]B confines miR-26a expression in cardiac fibroblast [54]. Therefore, it is worth to further investigate whether activated inflammatory mediators or NF-[kappa]B regulates miR-135a expression following silica internalization.

https://doi.org/10.1155/2020/1231243

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This subject is funded by the Hunan Natural Science Foundation(2018JJ2628).

References

[1] M. I. Greenberg, J. Waksman, and J. Curtis, "Silicosis: a review," Disease-a-Month, vol. 53, no. 8, pp. 394-416, 2007.

[2] C. C. Leung, I. T. S. Yu, and W. Chen, "Silicosis," The Lancet, vol. 379, no. 9830, pp. 2008-2018, 2012.

[3] K. H. Ohman, "Prevention of silica exposure and elimination of silicosis," American Industrial Hygiene Association Journal, vol. 39, no. 11, pp. 847-859, 1978.

[4] R. F. Hamilton Jr., S. A. Thakur, and A. Holian, "Silica binding and toxicity in alveolar macrophages," Free Radical Biology & Medicine, vol. 44, no. 7, pp. 1246-1258, 2008.

[5] G. Greenburg and E. D. Hay, "Cytodifferentiation and tissue phenotype change during transformation of embryonic lens epithelium to mesenchyme-like cells in vitro," Developmental Biology, vol. 115, no. 2, pp. 363-379, 1986.

[6] N. Rout-Pitt, N. Farrow, D. Parsons, and M. Donnelley, "Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology," Respiratory Research, vol. 19, no. 1, p. 136, 2018.

[7] N. A. Hosper, P. P. van den Berg, S. de Rond et al., "Epithelial-to-mesenchymal transition in fibrosis: collagen type I expression is highly upregulated after EMT, but does not contribute to collagen deposition," Experimental Cell Research, vol. 319, no. 19, pp. 3000-3009, 2013.

[8] C. Shimbori, J. Gauldie, and M. Kolb, "Extracellular matrix microenvironment contributes actively to pulmonary fibrosis," Current Opinion in Pulmonary Medicine, vol. 19, no. 5, pp. 446-452, 2013.

[9] N. W. Todd, I. G. Luzina, and S. P. Atamas, "Molecular and cellular mechanisms of pulmonary fibrosis," Fibrogenesis & Tissue Repair, vol. 5, no. 1, 2012.

[10] S. O'Reilly, "MicroRNAs in fibrosis: opportunities and challenges," Arthritis Research & Therapy, vol. 18, no. 1, 2016.

[11] G. Liu, A. Friggeri, Y. Yang et al., "miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis," The Journal of Experimental Medicine, vol. 207, no. 8, pp. 1589-1597, 2010.

[12] Y. Yang, M. B. Ishak Gabra, E. A. Hanse et al., "miR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1," Nature Communications, vol. 10, no. 1, p. 809, 2019.

[13] C. Lou and Y. Li, "Functional role of microRNA-135a in colitis," Journal of Inflammation, vol. 15, no. 1, 2018.

[14] A. Ahmad, W. Zhang, M. Wu, S. Tan, and T. Zhu, "Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes," Genes & Genomics, vol. 40, no. 3, pp. 243-251, 2018.

[15] Y. Wu, Y. Liu, Y. Pan et al., "MicroRNA-135a inhibits cardiac fibrosis induced by isoproterenol via TRPM7 channel," Biomedicine & Pharmacotherapy, vol. 104, pp. 252-260, 2018.

[16] F. He, F. Peng, X. Xia et al., "MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1," Diabetologia, vol. 57, no. 8, pp. 1726-1736, 2014.

[17] S. Polikepahad, J. M. Knight, A. O. Naghavi et al., "Proinflammatory role for let-7 microRNAS in experimental asthma," The Journal of Biological Chemistry, vol. 285, no. 39, pp. 30139-30149, 2010.

[18] R. H. Yu, L. M. Wang, and X. H. Hu, "MiR-135a Inhibitor Alleviates Pulmonary Arterial Hypertension Through [beta]-Catenin/GSK-3[beta] Signaling Pathway," European Review for Medical and Pharmacological Sciences, vol. 23, no. 21, pp. 9574-9581, 2019.

[19] H. W. Lee and S. H. Park, "Elevated microRNA-135a is associated with pulmonary arterial hypertension in experimental mouse model," Oncotarget, vol. 8, no. 22, pp. 35609-35618, 2017.

[20] H. Shi, Y. Ji, D. Zhang, Y. Liu, and P. Fang, "MiR-135a inhibits migration and invasion and regulates EMT-related marker genes by targeting KLF8 in lung cancer cells," Biochemical and Biophysical Research Communications, vol. 465, no. 1, pp. 125-130, 2015.

[21] M. Tsugita, N. Morimoto, M. Tashiro, K. Kinoshita, and M. Nakayama, "SR-B1 is a silica receptor that mediates canonical inflammasome activation," Cell Reports, vol. 18, no. 5, pp. 1298-1311,2017.

[22] H. Guo, J. B. Callaway, and J. P.-Y. Ting, "Inflammasomes: mechanism of action, role in disease, and therapeutics," Nature Medicine, vol. 21, no. 7, pp. 677-687, 2015.

[23] P. Broz and V. M. Dixit, "Inflammasomes: mechanism of assembly, regulation and signalling," Nature Reviews. Immunology, vol. 16, no. 7, pp. 407-420, 2016.

[24] B. Tian, Y. Zhao, H. Sun, Y. Zhang, J. Yang, and A. R. Brasier, "BRD4 mediates NF-[kappa]B-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation," American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 311, no. 6, pp. L1183-L1201, 2016.

[25] D. W. Porter, J. Ye, J. Ma et al., "Time course of pulmonary response of rats to inhalation of crystalline silica: NF-kappa B activation, inflammation, cytokine production, and damage," Inhalation Toxicology, vol. 14, no. 4, pp. 349-367, 2008.

[26] M. Di Giuseppe, F. Gambelli, G. W. Hoyle et al., "Systemic inhibition of NF-[kappa]B activation protects from silicosis," PLoS One, vol. 4, no. 5, p. e5689, 2009.

[27] A. Hoffmann, A. Levchenko, M. L. Scott, and D. Baltimore, "The Ikappa B-NF-kappa B Signaling Module: Temporal Control and Selective Gene Activation," Science, vol. 298, no. 5596, pp. 1241-1245, 2002.

[28] N. D. Perkins, "Integrating cell-signalling pathways with NF-[kappa]B and IKK function," Nature Reviews. Molecular Cell Biology, vol. 8, no. 1, pp. 49-62, 2007.

[29] P. F. Piguet, M. A. Collart, G. E. Grau, A. P. Sappino, and P. Vassalli, "Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis," Nature, vol. 344, no. 6263, pp. 245-247, 1990.

[30] N. Parameswaran and S. Patial, "Tumor necrosis factor-alpha signaling in macrophages," Critical Reviews in Eukaryotic Gene Expression, vol. 20, no. 2, pp. 87-103, 2010.

[31] G. Dvoriantchikova and D. Ivanov, "Tumor necrosis factor-alpha mediates activation of NF-[kappa]B and JNK signaling cascades in retinal ganglion cells and astrocytes in opposite ways," The European Journal of Neuroscience, vol. 40, no. 8, pp. 3171-3178, 2014.

[32] A. K. Hubbard, C. R. Timblin, A. Shukla, M. Rincon, and B. T. Mossman, "Activation of NF-[kappa]B-dependent gene expression by silica in lungs of luciferase reporter mice," American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 282, no. 5, pp. L968-L975, 2002.

[33] M. Ding, F. Chen, X. Shi, B. Yucesoy, B. Mossman, and V. Vallyathan, "Diseases caused by silica: mechanisms of injury and disease development," International Immunopharmacology, vol. 2, no. 2-3, pp. 173-182, 2002.

[34] M. Bodas and N. Vij, "The NFkB Signaling in Cystic Fibrosis Lung Disease: Pathophysiology and Therapeutic Potential," Discovery Medicine, vol. 9, no. 47, pp. 346-356, 2010.

[35] M. Sacks, J. Gordon, J. Bylander et al., "Silica-Induced Pulmonary Inflammation in Rats: Activation of NF-[kappa]B and Its Suppression by Dexamethasone," Biochemical and Biophysical Research Communications, vol. 253, no. 1, pp. 181-184, 1998.

[36] T. Ashcroft, J. M. Simpson, and V. Timbrell, "Simple method of estimating severity of pulmonary fibrosis on a numerical scale," Journal of Clinical Pathology, vol. 41, no. 4, pp. 467-470, 1988.

[37] K. J. Livak and T. D. Schmittgen, "Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-AACT Method," Methods, vol. 25, no. 4, pp. 402-408, 2001.

[38] M. G. Helal and E. Said, "Carvedilol attenuates experimentally induced silicosis in rats via modulation of P-AKT/m-TOR/TGF[beta]1 signaling," International Immunopharmacology, vol. 70, pp. 47-55, 2019.

[39] X. Wang, H. X. Wang, Y. L. Li et al., "MicroRNA Let-7i negatively regulates cardiac inflammation and fibrosis," Hypertension, vol. 66, no. 4, pp. 776-785, 2015.

[40] S. Roy, F. Benz, T. Luedde, and C. Roderburg, "The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis," Hepatobiliary Surgery and Nutrition, vol. 4, no. 1, pp. 24-33, 2015.

[41] R. Sessa and A. Hata, "Role of microRNAs in lung development and pulmonary diseases," Pulmonary Circulation, vol. 3, no. 2, pp. 315-328, 2013.

[42] T. Yang, Y. Liang, Q. Lin et al., "MiR-29 mediates TGF[beta]1-induced extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung fibroblasts," Journal of Cellular Biochemistry, vol. 114, no. 6, pp. 1336-1342, 2013.

[43] L. Huleihel, A. Ben-Yehudah, J. Milosevic et al., "Let-7d micro-RNA affects mesenchymal phenotypic properties of lung fibroblasts," American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 306, no. 6, pp. L534-L542, 2014.

[44] Y. Q. Deng, Y. Q. Yang, S. B. Wang et al., "Intranasal administration of lentiviral miR-135a regulates mast cell and allergen-induced inflammation by targeting GATA-3," PLoS One, vol. 10, no. 9, article e0139322, 2015.

[45] X. Yan, W. Li, L. Yang et al., "MiR-135a protects vascular endothelial cells against ventilator-induced lung injury by inhibiting PHLPP2 to activate PI3K/Akt pathway," Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, vol. 48, no. 3, pp. 1245-1258, 2018.

[46] D. M. Gomez Zubieta, M. A. Hamood, R. Beydoun, A. E. Pall, and K. C. Kondapalli, "MicroRNA-135a regulates NHE9 to inhibit proliferation and migration of glioblastoma cells," Cell Communication and Signaling, vol. 15, no. 1, p. 55, 2017.

[47] X. P. Mao, L. S. Zhang, B. Huang et al., "Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer," Journal of Translational Medicine, vol. 13, no. 1, p. 86, 2015.

[48] M. H. van der Ree, A. J. van der Meer, A. C. van Nuenen et al., "Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma," Alimentary Pharmacology & Therapeutics, vol. 43, no. 1, pp. 102-113, 2016.

[49] P. Trang, J. F. Wiggins, C. L. Daige et al., "Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice," Molecular Therapy, vol. 19, no. 6, pp. 1116-1122, 2011.

[50] H. Liang, C. Xu, Z. Pan et al., "The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis," Molecular Therapy, vol. 22, no. 6, pp. 1122-1133, 2014.

[51] S. Das, M. Kumar, V. Negi et al., "MicroRNA-326 Regulates Profibrotic Functions of Transforming Growth Factor-[beta] in Pulmonary Fibrosis," American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 5, pp. 882-892, 2014.

[52] L. Jiang, L. Yu, X. Zhang et al., "miR-892b Silencing Activates NF- B and Promotes Aggressiveness in Breast Cancer," Cancer Research, vol. 76, no. 5, pp. 1101-1111, 2016.

[53] X. Sun, B. Icli, A. K. Wara et al., "MicroRNA-181b regulates NF-[kappa]B-mediated vascular inflammation," The Journal of Clinical Investigation, vol. 122, no. 6, pp. 1973-1990, 2012.

[54] C. Wei, I. K. Kim, S. Kumar et al., "NF-[kappa]B mediated miR-26a regulation in cardiac fibrosis," Journal of Cellular Physiology, vol. 228, no. 7, pp. 1433-1442, 2013.

[55] B. Wang, S. H. Hsu, X. Wang et al., "Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2," Hepatology, vol. 59, no. 2, pp. 555-566, 2014.

[56] H. Francis, K. McDaniel, Y. Han et al., "Regulation of the extrinsic apoptotic pathway by microRNA-21 in alcoholic liver injury," The Journal of Biological Chemistry, vol. 289, no. 40, pp. 27526-27539, 2014.

[57] J. L. Gooch, C. King, C. E. Francis, P. S. Garcia, and Y. Bai, "Cyclosporine A alters expression of renal microRNAs: new insights into calcineurin inhibitor nephrotoxicity," PLoS One, vol. 12, no. 4, article e0175242, 2017.

Bin Xie, (1) Can Lu, (1) Chen Chen, (1,2) Jianhua Zhou, (1,2) and Zhenghao Deng [ID], (1,2)

(1) Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China

(2) Department of Pathology, School of Basic Medicine, Central South University, Changsha, Hunan 410013, China

Correspondence should be addressed to Zhenghao Deng; 205136@csu.edu.cn

Received 22 September 2019; Revised 21 January 2020; Accepted 14 May 2020; Published 17 June 2020

Academic Editor: Phileno Pinge-Filho

Caption: Figure 1: Silica induces pulmonary fibrosis in mice. (a) HE stain for lung sections 28 days following saline or silica instillation. Bar = 10 [micro]m. (b) The grading numerical scale for the severity of lung fibrosis. Scale 0 indicated the absence of fibrosis but scale 1 to 4 represented light to intense fibrosis. (c) Immunostaining of E- cadherin in lung sections of control or silica-instilled mice. Bar = 10 [micro]m. *** p < 0.001, compared to Ctrl.

Caption: Figure 2: Decreased expression of miR-135a in lung tissues from silica-instilled mice. (a-d) Expression of inflammatory mediators including IL-1b (a), TNF-[alpha] (b), TGF-[beta] (c), and IFN-y (d) in lung tissues from control and silica-instilled mice using real-time QF-PCR. (e) Expression of miR-135a in lung tissues from control and silica- instilled mice using real-time QF-PCR. (f) Correlation of miR-135a expression with fibrosis score. ** p < 0.01, *** p < 0.001.

Caption: Figure 3: miR-135a restoration in lung tissues attenuates pulmonary fibrosis. (a) The expression of miR-135a in lung tissues from mice instilled with LV-control or LV-miR-135a following saline or silica exposure using real-time QF-PCR. (b) HE stain for lung sections from mice instilled with LV-control or LV-miR-135a following saline or silica exposure. Bar = 10 [micro]m. (c) Fibrosis score of mice instilled with LV-control or LV-miR-135a following saline or silica exposure. (d-f) Immunostaining of E-cadherin (d), [alpha]-SMA (e), or vimentin (f) in lung sections from mice after instillation of LV-control or LV-miR-135a following saline or silica exposure. Bar = 10 [micro]m. * p < 0.05, ** p < 0.01, *** p < 0.001.

Caption: Figure 4: miR-135a restoration in lung tissues attenuates inflammatory response in silica-induced pulmonary fibrosis. (a-d) The expression of inflammatory mediators including IL-1b (a), TNF-[alpha] (b), TGF-[beta] (c), and IFN- y (d) in lung tissues from mice instilled with LV-control or LV-miR-135a following saline or silica exposure using real-time QF-PCR. * p < 0.05, ** p < 0.01, *** p < 0.001.

Caption: Figure 5: miR-135a restoration in lung tissues inhibits NF-[kappa]B signal in silica-induced pulmonary fibrosis. (a) Expression of p-p65, p65, and TLR4 in lung tissues from mice instilled with LV-control or LV-miR-135a following saline or silica exposure by WB. (b-d) Quantification of p-p65 (b), p65 (c), or TLR4 (d) expression from (a). n = 3. *** p < 0.001. (e) Expression of TLR4 and NF-[kappa]B components in BEAS-2B cells transfected with miR-135a mimic or inhibitor. (f-l) Quantitative expression of TLR4 and NF-[kappa]B components in (e). n = 3, ** p <0.01, *** p <0.001, when compared to Ctrl.

Caption: Figure 6: Inhibition of NF-[kappa]B improves miR-135a-mediated protective effects on silica-induced pulmonary fibrosis. (a) Expression of p-p65, p65, and TLR4 in lung tissues from mice instilled with LV-control or LV-miR-135a combined with PDTC treatment following silica exposure by WB. (b-d) Quantification of p-p65 (b), p65 (c), or TLR4 (d) expression from (a). n = 3. (E) HE stain for lung sections from mice instilled with LV-control or LV-miR-135a combined with PDTC treatment 28 days following silica exposure. Bar = 10 [micro]m. (F) Fibrosis score of mice instilled with LV- control or LV-miR-135a combined with PDTC treatment 28 days following silica exposure. (g-i) Immunostaining of E- cadherin (g), [alpha]-SMA (h), or vimentin (i) in lung sections from mice instilled with LV-control or LV-miR-135a combined with PDTC treatment 28 days following silica exposure. Bar = 10 [micro]m. * p < 0.05, *** p < 0.001.

Caption: Figure 7: Inhibition of NF-[kappa]B improves the anti-inflammatory effect of miR-135a in silica-induced pulmonary fibrosis. (a) Expression of miR-135a in lung tissues from mice instilled with LV-control or LV-miR-135a combined with PDTC treatment 28 days following silica exposure using real-time QF-PCR. (b-e) Expression of inflammatory mediators including IL-1b (b), TNF-[alpha] (c), TGF-[beta] (d), and IFN-y (e) in lung tissues from mice instilled with LV-control or LV-miR-135a combined with PDTC treatment 28 days following silica exposure using real-time QF-PCR. * p < 0.05, ** p < 0.01, *** p < 0.001.
Table 1: The sequence of specific primers for target genes.

Gene                    Primer

miR-135a        GGTATAGGGATTGGAGCCGTGG
IL-1[beta]     FTGAAATGCCACCTTTTGACAGT
                RTTCTCCACAGCCACAATGAGT
TNF-[alpha]     FAGCACAGAAAGCATGATCCG
                RCACCCCGAAGTTCAGTAGACA
IFN-y            FGCCACGGCACAGTCATTGA
                RTGCTGATGGCCTGATTGTCTT
TGF-[beta]       FCTCCCGTGGCTTCTAGTGC
               RGCCTTAGTTTGGACAGGATCTG
[beta]-Actin   FACATCCGTAAAGACCTCTATGCC
                RTACTCCTGCTTGCTGATCCAC
U6                FCTCGCTTCGGCAGCACA
                RAACGCTTCACGAATTTGCGT
COPYRIGHT 2020 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Xie, Bin; Lu, Can; Chen, Chen; Zhou, Jianhua; Deng, Zhenghao
Publication:Mediators of Inflammation
Date:Jun 30, 2020
Words:6542
Previous Article:Autophagy Contributes to Host Immunity and Protection against Zika Virus Infection via Type IIFN Signaling.
Next Article:Decoy Receptor 3 Promotes Preosteoclast Cell Death via Reactive Oxygen Species-Induced Fas Ligand Expression and the IL-1[alpha]/IL-1 Receptor...
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |